Novo Nordisk and Sanofi urged a federal appeals court in Philadelphia to reverse a district judge’s ruling that their denials on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.
Novo Nordisk, Sanofi, and Feds Trade Arguments in 340B Contract Pharmacy Litigation
Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
